Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885823571> ?p ?o ?g. }
- W2885823571 endingPage "242" @default.
- W2885823571 startingPage "215" @default.
- W2885823571 abstract "Over the last years, targeted anti-cancer therapy with small-molecule inhibitors and antibodies moved to the forefront as a strategy to treat hematological cancers. These novel agents showed outstanding effects in treatment of patients, often irrespective of their underlying genetic features. However, evolution and selection of subclones with continuous treatment leads to disease relapse and resistance toward these novel drugs. Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor for selective targeting of B-cell lymphoma 2 (BCL2). Venetoclax is in clinical development and shows high efficacy and safety in particular in the treatment of chronic lymphocytic leukemia (CLL), but preliminarily also in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The most important and impressive outcomes of venetoclax treatment include a rapid induction of apoptosis and drastic reduction of the tumor bulk within a few hours after administration. Venetoclax was approved by the FDA and EMA in 2016 for patients with previously treated CLL with del(17p13) and patients failing B cell receptor signaling inhibitors (EMA only), on the basis of a single-arm phase II trial demonstrating a tremendous response rate of 79% with complete remission in 20% of cases and an estimated 1-year progression-free survival of 72%. This review focuses on the mode of action, the preclinical models, and outcomes from various clinical trials with venetoclax in different hematologic cancers as well as future development." @default.
- W2885823571 created "2018-08-22" @default.
- W2885823571 creator A5019866348 @default.
- W2885823571 creator A5037750452 @default.
- W2885823571 creator A5051011523 @default.
- W2885823571 date "2018-01-01" @default.
- W2885823571 modified "2023-10-16" @default.
- W2885823571 title "Venetoclax: Targeting BCL2 in Hematological Cancers" @default.
- W2885823571 cites W122353466 @default.
- W2885823571 cites W1481927174 @default.
- W2885823571 cites W1515607020 @default.
- W2885823571 cites W1527354001 @default.
- W2885823571 cites W1862870226 @default.
- W2885823571 cites W1913179054 @default.
- W2885823571 cites W1913661233 @default.
- W2885823571 cites W1950569589 @default.
- W2885823571 cites W1963571549 @default.
- W2885823571 cites W1975301877 @default.
- W2885823571 cites W1978244665 @default.
- W2885823571 cites W1983386156 @default.
- W2885823571 cites W1985563073 @default.
- W2885823571 cites W1986688227 @default.
- W2885823571 cites W1986924929 @default.
- W2885823571 cites W1987638148 @default.
- W2885823571 cites W1991213319 @default.
- W2885823571 cites W2000894919 @default.
- W2885823571 cites W2001543531 @default.
- W2885823571 cites W2002934318 @default.
- W2885823571 cites W2008898220 @default.
- W2885823571 cites W2023111945 @default.
- W2885823571 cites W2024996523 @default.
- W2885823571 cites W2027395744 @default.
- W2885823571 cites W2028526641 @default.
- W2885823571 cites W2036861455 @default.
- W2885823571 cites W2052846308 @default.
- W2885823571 cites W2057259026 @default.
- W2885823571 cites W2057315090 @default.
- W2885823571 cites W2059500638 @default.
- W2885823571 cites W2062132637 @default.
- W2885823571 cites W2062133747 @default.
- W2885823571 cites W2062358377 @default.
- W2885823571 cites W2063176993 @default.
- W2885823571 cites W2064937772 @default.
- W2885823571 cites W2069448515 @default.
- W2885823571 cites W2071599920 @default.
- W2885823571 cites W2081379689 @default.
- W2885823571 cites W2083113305 @default.
- W2885823571 cites W2085419794 @default.
- W2885823571 cites W2086671133 @default.
- W2885823571 cites W2088634057 @default.
- W2885823571 cites W2088845956 @default.
- W2885823571 cites W2102461774 @default.
- W2885823571 cites W2105594055 @default.
- W2885823571 cites W2108206643 @default.
- W2885823571 cites W2111988922 @default.
- W2885823571 cites W2113278680 @default.
- W2885823571 cites W2117692326 @default.
- W2885823571 cites W2119316461 @default.
- W2885823571 cites W2122479144 @default.
- W2885823571 cites W2123621979 @default.
- W2885823571 cites W2126322093 @default.
- W2885823571 cites W2126709547 @default.
- W2885823571 cites W2127720974 @default.
- W2885823571 cites W2132740145 @default.
- W2885823571 cites W2134138207 @default.
- W2885823571 cites W2146983373 @default.
- W2885823571 cites W2147852317 @default.
- W2885823571 cites W2148686659 @default.
- W2885823571 cites W2150680216 @default.
- W2885823571 cites W2153056550 @default.
- W2885823571 cites W2153923291 @default.
- W2885823571 cites W2168632005 @default.
- W2885823571 cites W2169008732 @default.
- W2885823571 cites W2172242534 @default.
- W2885823571 cites W2192121806 @default.
- W2885823571 cites W2215798291 @default.
- W2885823571 cites W2269578998 @default.
- W2885823571 cites W2277533260 @default.
- W2885823571 cites W2291176625 @default.
- W2885823571 cites W2297120379 @default.
- W2885823571 cites W2338693134 @default.
- W2885823571 cites W2343244371 @default.
- W2885823571 cites W2369297677 @default.
- W2885823571 cites W2409945629 @default.
- W2885823571 cites W2511409090 @default.
- W2885823571 cites W2516164871 @default.
- W2885823571 cites W2517675534 @default.
- W2885823571 cites W2518387705 @default.
- W2885823571 cites W2534349779 @default.
- W2885823571 cites W2549463667 @default.
- W2885823571 cites W2572899914 @default.
- W2885823571 cites W2573476619 @default.
- W2885823571 cites W2574117271 @default.
- W2885823571 cites W2581891628 @default.
- W2885823571 cites W2582696216 @default.
- W2885823571 cites W2587371140 @default.
- W2885823571 cites W2611007981 @default.
- W2885823571 cites W2614021025 @default.